manufacture and commercialise the drug candidate “SON-080” for the treatment of diabetic peripheral neuropathy in India. According to a press statement, “SON-080” is Sonnet’s proprietary ...

The causal relationship of liver disease to neuropathy has been questioned. This study was designed to evaluate the incidence and character of peripheral neuropathy in patients with liver cirrhosis.

Discover the latest drugs and treatment options in the Peripheral Arterial Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Peripheral Arterial Disease Pipeline Outlook Key ...

Alkem Laboratories partners with Sonnet BioTherapeutics to develop and commercialize SON-080, a potential treatment for diabetic peripheral neuropathy in India. The drug has shown promising nerve ...

In addition, these factors also stimulate inflammation-related damage to the nervous system, contributing to ...

Some diseases producing liver dysfunction can independently cause peripheral neuropathy. Hence, a cause and effect relationship between liver disease and neuropathy has been questioned.

Mumbai: Alkem Laboratories Ltd. has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc to develop, manufacture and commercialise the drug candidate “SON-080” for the ...

If these symptoms sound familiar, and you are a patient with type 1 or type 2 diabetes, you may be experiencing symptoms associated with diabetic peripheral neuropathy ... good control of your blood ...